6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Peripheral Artery Disease
University of IoanninaSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Peripheral Artery Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Plavix Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | BBB |
Acetylsalicylic Acid Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | BBB |
Ranolazine Colorado Prevention Center | Phase 4 | BB |
Ticagrelor AstraZeneca | Phase 3 | BB |
Ezetimibe University of Oxford | Phase 3 | B |
View all 14 →
Same molecule, other indications
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →